# Phase 6: Premarketing (IND) Safety Reports

## Requirements Specification for Claude Code

**Version:** 1.0  
**Phase:** 6 of 12  
**Estimated Duration:** 2 months  
**Prerequisites:** Phase 1, Phase 2, Phase 3, and Phase 4 completed (Phase 5 optional but recommended)

---

## 1. Phase Overview

### 1.1 Objective

Add support for premarketing safety reports including Investigational New Drug (IND) safety reports per 21 CFR 312.32 and IND-exempt bioavailability/bioequivalence (BA/BE) study reports. This phase enables sponsors to manage clinical trial safety data, track blinded/unblinded cases, assess causality and expectedness against the Investigator Brochure, generate Form FDA 3500A, and submit electronically via E2B(R3) XML.

### 1.2 Success Criteria

- [ ] IND safety reports can be created with all required fields
- [ ] Study/protocol configuration with sites and investigators
- [ ] Blinding status tracked with unblinding workflow
- [ ] Expectedness assessment against Investigator Brochure
- [ ] Causality assessment (investigator and sponsor)
- [ ] 7-day and 15-day expedited timelines enforced
- [ ] IND-exempt BA/BE study reports supported
- [ ] Form FDA 3500A PDF generation
- [ ] E2B(R3) XML generation with IND-specific elements
- [ ] IND Annual Safety Report data aggregation
- [ ] Protocol deviation tracking linked to cases

### 1.3 Out of Scope for Phase 6

- Cosmetics reporting (Phase 7)
- Signal detection analytics (Phase 8)
- External PV database integration (Phase 9)
- Development Safety Update Report (DSUR) generation
- Electronic IRB submission

### 1.4 Dependencies

- **Phase 1-4 Complete**: Core case management, submission, workflow, PSR
- **Phase 5 Recommended**: MedDRA/WHO Drug coding enhances IND reporting
- **Active IND**: IND number must be registered with FDA

---

## 2. Background Information

### 2.1 Regulatory Framework (21 CFR 312.32)

IND safety reporting requirements apply to sponsors of clinical studies conducted under an IND application.

#### 2.1.1 Key Definitions

| Term | Definition (21 CFR 312.32(a)) |
|------|------------------------------|
| **Adverse Event (AE)** | Any untoward medical occurrence associated with drug use, whether or not considered drug related |
| **Serious AE/SAE** | Results in death, is life-threatening, requires hospitalization, causes disability, congenital anomaly, or other medically important event |
| **Suspected Adverse Reaction** | AE where there is reasonable possibility the drug caused the event (evidence of causal relationship) |
| **Unexpected** | Not listed in Investigator Brochure, or not at specificity/severity observed |
| **Life-threatening** | Places subject at immediate risk of death (not hypothetical) |

#### 2.1.2 Reporting Requirements

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    IND SAFETY REPORTING DECISION TREE                    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                    â”‚
                         Adverse Event Occurs
                                    â”‚
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â–¼                               â–¼
              Is it Serious?                  Not Serious
                    â”‚                               â”‚
          â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”                      â–¼
          â–¼                 â–¼              Collect in Annual
    Yes, Serious      No, Not Serious         Report Only
          â”‚
          â–¼
    Is there evidence
    of causal relationship?
          â”‚
    â”Œâ”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”
    â–¼           â–¼
   Yes         No
    â”‚           â”‚
    â–¼           â–¼
  Suspected   Adverse Event
  Adverse     (not suspected)
  Reaction    Report per protocol
    â”‚
    â–¼
Is it Unexpected?
(not in IB at specificity/severity)
    â”‚
    â”Œâ”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”
    â–¼           â–¼
   Yes         No
    â”‚           â”‚
    â–¼           â–¼
  SUSAR     Expected SAR
  Report    Report in
  to FDA    Annual Report
    â”‚
    â–¼
Is it Fatal or
Life-threatening?
    â”‚
    â”Œâ”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”
    â–¼           â–¼
   Yes         No
    â”‚           â”‚
    â–¼           â–¼
  7-Day      15-Day
  Report     Report
```

#### 2.1.3 Reporting Timelines

| Report Type | Timeline | Submission Method |
|-------------|----------|-------------------|
| **Fatal/Life-threatening SUSAR** | 7 calendar days | E2B(R3) XML or Form 3500A |
| **Other Serious Unexpected SAR** | 15 calendar days | E2B(R3) XML or Form 3500A |
| **Follow-up to 7-day report** | 15 calendar days from initial | E2B(R3) XML or Form 3500A |
| **Non-serious / Expected SAEs** | IND Annual Report | Aggregate summary |
| **Safety Report Follow-up** | 15 calendar days from new info | E2B(R3) XML or Form 3500A |

### 2.2 E2B(R3) IND-Specific Requirements

#### 2.2.1 Routing Identifiers for IND Reports

| Field | Value |
|-------|-------|
| **Batch Receiver (N.1.4)** | ZZFDA_PREMKT |
| **Message Receiver - CDER (N.2.r.3)** | CDER_IND |
| **Message Receiver - CBER (N.2.r.3)** | CBER_IND |

#### 2.2.2 IND-Specific Data Elements

```xml
<!-- A.1.6: IND Number -->
<outboundRelationship2 typeCode="REFR">
  <relatedInvestigation classCode="INVSTG">
    <id root="2.16.840.1.113883.3.989.2.1.3.3" extension="123456"/>
    <!-- IND number format: 6 digits -->
  </relatedInvestigation>
</outboundRelationship2>

<!-- A.2.3.3: Study Registration (Protocol/Study ID) -->
<outboundRelationship2 typeCode="CAUS">
  <observation classCode="OBS" moodCode="EVN">
    <code code="C.5.4" codeSystem="2.16.840.1.113883.3.989.2.1.1.19"/>
    <value xsi:type="ST">Protocol ABC-123</value>
  </observation>
</outboundRelationship2>

<!-- C.5.4: Study Type Where Reaction Was Observed -->
<value xsi:type="CE" code="1" codeSystem="2.16.840.1.113883.3.989.2.1.3.12"/>
<!-- 1=Clinical trials, 2=Individual patient use, 3=Other studies -->

<!-- FDA.C.1.7.1: Type of Report (IND-specific) -->
<observation>
  <code code="FDA.C.1.7.1" codeSystem="2.16.840.1.113883.3.989.2.1.1.5"/>
  <value xsi:type="CE" code="6" codeSystem="2.16.840.1.113883.3.989.2.1.1.5"/>
  <!-- 5=15-day, 6=7-day, 7=IND Annual Report, 8=BA/BE -->
</observation>
```

### 2.3 IND-Exempt BA/BE Studies

Bioavailability/Bioequivalence studies may be exempt from IND requirements under 21 CFR 320.31(d)(3) but still require safety reporting:

| Aspect | Requirement |
|--------|-------------|
| **Scope** | BA/BE studies supporting ANDAs |
| **What to Report** | Serious adverse events |
| **Timeline** | 15 calendar days |
| **Method (until Apr 2026)** | Form FDA 3500A to ogd-premarketsafetyreports@fda.hhs.gov |
| **Method (after Apr 2026)** | E2B(R3) XML via ESG (mandatory) |
| **Message Receiver** | CDER_IND_EXEMPT_BA_BE |

### 2.4 Form FDA 3500A Structure

The MedWatch 3500A form for mandatory reporting includes:

| Section | Content |
|---------|---------|
| **A. Patient Information** | Demographics, weight, age, ethnicity |
| **B. Adverse Event** | Event description, dates, outcomes, seriousness |
| **C. Suspect Product(s)** | Drug name, dose, dates, indication |
| **D. Suspect Medical Device** | (Not applicable for drug IND) |
| **E. Initial Reporter** | Name, address, occupation |
| **F. For Use by Manufacturers** | Report type, dates |
| **G. Manufacturer Information** | Contact, IND/NDA number, report source |
| **H. Device Manufacturers Only** | (Not applicable for drug IND) |

---

## 3. Functional Requirements

### 3.1 Study and Protocol Management

#### REQ-STUDY-001: Study Configuration
```
As an administrator
I want to configure clinical studies
So that IND cases can be properly linked and tracked

Study Fields:
- Study ID (internal)
- Protocol number
- Study title
- IND number(s) - can have multiple
- Sponsor name
- Phase (1, 1/2, 2, 2/3, 3, 3b, 4)
- Study design (randomized, open-label, etc.)
- Therapeutic area
- Indication
- Investigational product(s)
- Study status (planned, enrolling, active, completed, terminated)
- First patient first visit (FPFV) date
- Last patient last visit (LPLV) date
- Investigator Brochure version
- Target enrollment

Acceptance Criteria:
- Study CRUD operations
- Multiple INDs per study supported
- Study linked to cases
- Study status tracked
- IB version tracked for expectedness
```

#### REQ-STUDY-002: Study Site Management
```
As an administrator
I want to manage study sites
So that cases can be linked to sites and investigators

Site Fields:
- Site number
- Site name
- Institution name
- Principal Investigator name
- Sub-investigators
- Address (street, city, state, country)
- Phone, fax, email
- IRB name and approval date
- Site status (active, closed, suspended)
- First patient enrolled date
- Country

Acceptance Criteria:
- Sites linked to studies
- Multiple investigators per site
- Site can be in multiple studies
- Site status tracked
- Address includes country for foreign sites
```

#### REQ-STUDY-003: Investigator Brochure Reference
```
As an administrator
I want to manage Investigator Brochure versions
So that expectedness can be assessed against current IB

IB Fields:
- IB version number
- Effective date
- Document file (PDF upload)
- Known adverse reactions list
  - MedDRA PT code
  - Severity documented
  - Frequency documented
- Change summary from previous version

Acceptance Criteria:
- Multiple IB versions per study
- Known reactions list for expectedness lookup
- IB effective date determines which version to use
- Link to uploaded PDF document
- Track changes between versions
```

### 3.2 IND Case Management

#### REQ-IND-001: IND Case Type
```
As a user
I want to create IND safety reports
So that clinical trial adverse events are properly documented

Case Type: IND Safety Report

Additional Fields (beyond standard ICSR):
- Study/Protocol selection
- IND number (auto-populated from study)
- Site selection
- Subject number (randomization ID)
- Is subject blinded? (Yes/No)
- Treatment arm (if unblinded)
- Study day of event onset
- Date of first dose
- Date of last dose
- Date informed of event

Acceptance Criteria:
- IND case type selectable
- All IND-specific fields captured
- Link to configured study
- Site selection from study sites
- Subject number tracked
- Blinding status captured
```

#### REQ-IND-002: Causality Assessment
```
As a user
I want to document causality assessments
So that the relationship between drug and event is characterized

Causality Categories:
- Related (definite causal relationship)
- Probably related (likely causal)
- Possibly related (could be causal)
- Unlikely related (doubtful causal)
- Not related (no causal relationship)
- Not assessable (insufficient information)

Assessment Sources:
1. Investigator assessment (required)
2. Sponsor assessment (required)
3. Independent assessor (optional)

Assessment Factors:
- Temporal relationship
- Dechallenge/rechallenge results
- Alternative explanations
- Biological plausibility
- Dose-response relationship

Acceptance Criteria:
- Both investigator and sponsor assessment required
- Assessment categories standardized
- Justification text captured
- If assessments differ, explanation required
- Date of each assessment tracked
```

#### REQ-IND-003: Expectedness Assessment
```
As a user
I want to assess whether an event is expected
So that correct reporting requirements are applied

Expectedness Determination:
- Is event listed in current IB? (Yes/No)
- If listed, is severity as documented? (Yes/No)
- If listed, is frequency as documented? (Yes/No)
- Reference IB section/page

Expectedness Result:
- Expected: Listed in IB at observed specificity/severity
- Unexpected: Not listed OR listed but more severe/specific

Acceptance Criteria:
- Compare reaction against IB known reactions
- Suggest expected/unexpected based on IB lookup
- User confirms or overrides assessment
- Justification required for unexpected determination
- IB version used for assessment tracked
```

#### REQ-IND-004: IND Reporting Timeline Calculation
```
As a user
I want the system to calculate due dates
So that regulatory timelines are met

Timeline Rules:
- Day 0 = Date sponsor informed of event
- Fatal/life-threatening SUSAR: 7 calendar days
- Other SUSAR: 15 calendar days
- Follow-up to 7-day: 15 calendar days from initial report
- Follow-up to 15-day: 15 calendar days from new info

SUSAR Criteria (all must be true):
- Serious (meets seriousness criteria)
- Unexpected (per IB)
- Suspected adverse reaction (evidence of causality)

Acceptance Criteria:
- Due date auto-calculated
- 7-day vs 15-day determined by life-threatening status
- Due date displayed prominently
- Overdue reports highlighted
- Non-SUSAR reports tracked for annual report
```

### 3.3 Blinding Management

#### REQ-BLIND-001: Blinded Case Handling
```
As a user
I want to manage blinded cases
So that treatment assignment is protected when appropriate

Blinded Case Rules:
- Treatment arm hidden/masked
- Subject number visible
- Event details fully captured
- Causality may be limited by blinding

Blinded Data Display:
- Treatment shows as "Blinded"
- Dose may show as "As per protocol"
- Product name shows investigational product name

Acceptance Criteria:
- Blinded indicator on case
- Treatment arm hidden when blinded
- All other data captured normally
- Blinded cases can be reported
- Blinding status included in XML when blinded
```

#### REQ-BLIND-002: Unblinding Workflow
```
As a user
I want to unblind a case when appropriate
So that treatment information can be assessed and reported

Unblinding Triggers:
- Serious unexpected event requiring treatment knowledge
- Medical emergency
- Sponsor safety assessment
- Regulatory request
- Study completion/database lock

Unblinding Process:
1. Request unblinding with reason
2. Approval required (if configured)
3. Treatment assignment revealed
4. Unblinding date/time recorded
5. Unblinding reason documented
6. Case updated with treatment info

Acceptance Criteria:
- Unblinding request workflow
- Approval requirement configurable
- Unblinding reason captured
- Date/time of unblinding recorded
- Who unblinded tracked
- Treatment arm populated after unblinding
- Audit trail of unblinding
```

#### REQ-BLIND-003: Unblinded Case Update
```
As a user
I want to update a case after unblinding
So that complete information is submitted to FDA

Post-Unblinding Updates:
- Treatment arm revealed
- Actual dose information
- Re-assess causality with full information
- Update expectedness if needed
- Determine if follow-up report needed

Acceptance Criteria:
- Treatment information editable after unblinding
- Causality re-assessment prompted
- Follow-up report created if changes material
- Original blinded report linked to follow-up
```

### 3.4 IND-Exempt BA/BE Studies

#### REQ-BABE-001: BA/BE Study Configuration
```
As an administrator
I want to configure BA/BE studies
So that safety reports can be properly tracked

BA/BE Study Fields:
- Protocol number
- Study design (crossover, parallel, replicate)
- Test product (generic)
- Reference product (brand)
- Active ingredient
- Dosage form
- Strength
- Population (healthy volunteers / patients)
- Sponsor name
- Pre-ANDA number (if assigned)

Acceptance Criteria:
- BA/BE study type distinct from IND
- No IND number required
- Test and reference products tracked
- Pre-ANDA number optional
```

#### REQ-BABE-002: BA/BE Safety Report
```
As a user
I want to create BA/BE safety reports
So that serious events from BA/BE studies are reported

BA/BE Report Fields:
- Study/protocol selection
- Subject number
- Test or reference product
- Event details (same as ICSR)
- Seriousness criteria
- Causality assessment

Acceptance Criteria:
- BA/BE case type selectable
- Link to configured BA/BE study
- Simplified compared to IND (no blinding)
- 15-day timeline for all serious events
- Submission to OGD (or ESG after Apr 2026)
```

### 3.5 Form FDA 3500A Generation

#### REQ-3500A-001: PDF Form Generation
```
As a user
I want to generate Form FDA 3500A
So that I can submit via non-electronic methods if needed

Form Sections to Populate:
A. Patient Information
   - Initials or identifier
   - Age, sex, weight
   - Ethnicity, race
   
B. Adverse Event or Product Problem
   - Event description
   - Date of event
   - Date of report
   - Outcomes (death, hospitalization, etc.)
   - Relevant tests/lab data
   - Medical history
   
C. Suspect Product(s)
   - Product name
   - Dose, frequency, route
   - Therapy dates
   - Diagnosis for use
   - Event abated on stop?
   - Event reappear on restart?
   - Concomitant products
   
E. Initial Reporter
   - Name and contact info
   - Health professional? (Yes/No)
   - Occupation
   
G. Manufacturer Information
   - Contact information
   - IND/NDA/ANDA number
   - Protocol number
   - Report type (7-day, 15-day, follow-up)
   - Date received from investigator
   - Report source

Acceptance Criteria:
- Generate fillable PDF
- All case data mapped to form fields
- Form validates required fields
- Date formatting correct (dd-mmm-yyyy)
- Narrative fits in available space (truncate with continuation)
- Attachment support for long narratives
```

#### REQ-3500A-002: 3500A Form Preview
```
As a user
I want to preview the 3500A form before finalizing
So that I can verify data accuracy

Preview Features:
- View populated PDF in browser
- Highlight empty required fields
- Side-by-side comparison with case data
- Edit case and regenerate
- Download draft watermarked PDF

Acceptance Criteria:
- Preview renders in browser
- Required fields highlighted if empty
- Comparison view available
- Edits trigger regeneration
- Draft watermark on preview
```

### 3.6 E2B(R3) IND XML Generation

#### REQ-XML-IND-001: IND-Specific XML Elements
```
As the system
I need to generate E2B(R3) XML with IND elements
So that electronic submissions are properly routed

IND-Specific Elements:
- Batch Receiver: ZZFDA_PREMKT
- Message Receiver: CDER_IND or CBER_IND
- IND Number (A.1.6)
- Protocol Number (A.2.3.3)
- Study Type = Clinical Trial (C.5.4)
- Report Type: 7-day (6) or 15-day (5)
- Blinding status
- Causality assessments

Acceptance Criteria:
- Routing IDs correct for IND
- IND number in correct format (6 digits)
- Protocol number included
- Report type indicates 7-day vs 15-day
- Blinding status included
- Both causality assessments included
- Validates against FDA schema
```

#### REQ-XML-IND-002: BA/BE XML Generation
```
As the system
I need to generate E2B(R3) XML for BA/BE studies
So that electronic submissions are properly routed

BA/BE-Specific Elements:
- Batch Receiver: ZZFDA_PREMKT
- Message Receiver: CDER_IND_EXEMPT_BA_BE
- Pre-ANDA number (if available)
- Protocol number
- Report Type: BA/BE (8)

Acceptance Criteria:
- Routing to correct BA/BE queue
- Pre-ANDA number if assigned
- Report type indicates BA/BE
- Validates against FDA schema
```

### 3.7 IND Annual Safety Report

#### REQ-ANNUAL-001: Annual Report Data Collection
```
As a user
I want to aggregate safety data for the annual report
So that IND annual report requirements are met

Annual Report Data:
- All SAEs in reporting period
- Line listing of ICSRs by category:
  - Serious unexpected (submitted as 7/15-day)
  - Serious expected
  - Non-serious events
- Summary tabulations:
  - By system organ class
  - By preferred term
  - By seriousness criteria
  - By causality
  - By outcome
- Narrative summary of safety findings
- IB update recommendations

Acceptance Criteria:
- Date range selection for annual period
- All relevant cases aggregated
- Categorization by report type
- Summary statistics calculated
- Export to Excel for inclusion in annual report
- Filter by study/IND
```

#### REQ-ANNUAL-002: Annual Report Generation
```
As a user
I want to generate annual report content
So that I can prepare the IND annual report

Generated Content:
- Case line listing table
- Summary tabulations (formatted)
- Event frequency tables
- Narrative template with auto-populated stats

Acceptance Criteria:
- Line listing exportable to Excel
- Summary tables formatted
- Narrative template with placeholders
- Review and approval workflow
- Track submission to FDA
```

### 3.8 Protocol Deviation Tracking

#### REQ-DEVIATION-001: Deviation Recording
```
As a user
I want to record protocol deviations
So that deviations related to safety events are documented

Deviation Fields:
- Deviation ID
- Deviation date
- Subject number
- Site
- Deviation category:
  - Inclusion/exclusion criteria
  - Informed consent
  - Prohibited medication
  - Dose modification
  - Visit schedule
  - Specimen collection
  - Other
- Description
- Impact on subject safety
- Impact on data integrity
- Corrective action taken
- Reported to IRB? (date)
- Reported to sponsor? (date)

Acceptance Criteria:
- Deviation recorded independently
- Can link deviation to safety case
- Multiple deviations per case supported
- IRB notification tracked
- Deviation history searchable
```

#### REQ-DEVIATION-002: Deviation-Case Linking
```
As a user
I want to link deviations to safety cases
So that related information is connected

Linking Features:
- Link existing deviation to case
- Create new deviation from case
- View linked deviations on case
- View linked cases on deviation
- Include deviation in narrative

Acceptance Criteria:
- Many-to-many relationship supported
- Linked deviations visible on case
- Deviation info can be included in narrative
- Deviation summary in XML if relevant
```

### 3.9 Investigator Notification

#### REQ-NOTIFY-001: Investigator Safety Notification
```
As a sponsor
I want to notify investigators of safety findings
So that 21 CFR 312.32(c)(1)(iv) requirements are met

Notification Triggers:
- SUSAR reported to FDA
- IB update with new safety information
- Important safety findings

Notification Content:
- Event summary
- Product information
- Action required (if any)
- Updated IB (if applicable)

Acceptance Criteria:
- Generate investigator notification letter
- Track distribution to all sites
- Document receipt acknowledgment
- Template-based notifications
- IRB copy indicator
```

---

## 4. User Interface Requirements

### 4.1 Study Configuration Interface

#### REQ-UI-STUDY-001: Study Setup
```
Study configuration screen:

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Study Configuration                                         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ Protocol Number: [ABC-001-2026_______________]             â”‚
â”‚ Study Title: [Phase 2 Study of Drug X in Diabetes___]      â”‚
â”‚                                                             â”‚
â”‚ IND Number(s):                                             â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ [123456] - CDER  [Remove]                              â”‚ â”‚
â”‚ â”‚ [+ Add IND]                                             â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ Phase: [Phase 2 â–¼]    Design: [Randomized, Double-Blind â–¼] â”‚
â”‚                                                             â”‚
â”‚ Sponsor: [Acme Pharmaceuticals_____________]               â”‚
â”‚ Therapeutic Area: [Endocrinology â–¼]                        â”‚
â”‚ Indication: [Type 2 Diabetes Mellitus_______]              â”‚
â”‚                                                             â”‚
â”‚ Investigational Product(s):                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ Drug X 100mg Tablet                         [Remove]   â”‚ â”‚
â”‚ â”‚ Drug X 200mg Tablet                         [Remove]   â”‚ â”‚
â”‚ â”‚ [+ Add Product]                                         â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ Status: [Active â–¼]                                         â”‚
â”‚ FPFV Date: [2026-01-15]    Target Enrollment: [500]        â”‚
â”‚                                                             â”‚
â”‚ Current IB Version: v5.0 (2025-12-01)  [Manage IB]        â”‚
â”‚                                                             â”‚
â”‚        [Cancel]  [Save Study]                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.2 IND Case Entry Interface

#### REQ-UI-IND-001: IND Case Header
```
IND case header section:

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ IND Safety Report                                           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ Study: [ABC-001-2026: Phase 2 Study of Drug X â–¼]           â”‚
â”‚                                                             â”‚
â”‚ IND: 123456 (auto)    Center: CDER (auto)                  â”‚
â”‚                                                             â”‚
â”‚ Site: [Site 101 - Johns Hopkins â–¼]                         â”‚
â”‚ Principal Investigator: Dr. Jane Smith (auto)              â”‚
â”‚                                                             â”‚
â”‚ Subject Number: [SUBJ-2026-0042_____]                      â”‚
â”‚                                                             â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ âš ï¸ Blinding Status                                      â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚ Is subject blinded? â— Yes  â—‹ No                        â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚ Treatment Arm: [Blinded - Not Available]               â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚ [Request Unblinding]                                    â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ Date Informed of Event: [2026-01-20] ğŸ“…                    â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.3 Causality Assessment Interface

#### REQ-UI-CAUSALITY-001: Dual Causality Entry
```
Causality assessment section:

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Causality Assessment                                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ INVESTIGATOR ASSESSMENT                                     â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚ Relationship to Study Drug:                                 â”‚
â”‚ â—‹ Related  â—‹ Probably Related  â— Possibly Related          â”‚
â”‚ â—‹ Unlikely Related  â—‹ Not Related  â—‹ Not Assessable        â”‚
â”‚                                                             â”‚
â”‚ Assessment Date: [2026-01-22]                              â”‚
â”‚ Assessor: Dr. Jane Smith (Investigator)                    â”‚
â”‚                                                             â”‚
â”‚ Justification:                                              â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ Temporal relationship present. Event occurred 3 days   â”‚ â”‚
â”‚ â”‚ after dose increase. No clear alternative etiology.    â”‚ â”‚
â”‚ â”‚ Rechallenge not performed.                             â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚ SPONSOR ASSESSMENT                                          â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚ Relationship to Study Drug:                                 â”‚
â”‚ â—‹ Related  â— Probably Related  â—‹ Possibly Related          â”‚
â”‚ â—‹ Unlikely Related  â—‹ Not Related  â—‹ Not Assessable        â”‚
â”‚                                                             â”‚
â”‚ Assessment Date: [2026-01-23]                              â”‚
â”‚ Assessor: [Dr. Medical Monitor â–¼]                          â”‚
â”‚                                                             â”‚
â”‚ Justification:                                              â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ Agree with investigator temporal relationship. Similar â”‚ â”‚
â”‚ â”‚ events seen in other subjects. Biological plausibility â”‚ â”‚
â”‚ â”‚ based on mechanism of action. Upgrading to Probably.   â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ âš ï¸ Assessments differ - explanation required               â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ Sponsor upgraded based on aggregate safety data showingâ”‚ â”‚
â”‚ â”‚ pattern across multiple subjects.                      â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.4 Expectedness Assessment Interface

#### REQ-UI-EXPECT-001: IB Lookup
```
Expectedness assessment section:

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Expectedness Assessment                                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ Reaction: Hepatic enzyme increased (PT: 10019678)          â”‚
â”‚ Severity Reported: Grade 3 (Severe)                        â”‚
â”‚                                                             â”‚
â”‚ Reference IB: Version 5.0 (Effective: 2025-12-01)         â”‚
â”‚                                                             â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ IB Lookup Result                                        â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚ âœ“ Event IS listed in IB (Section 5.3.2, Page 42)       â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚ IB Entry:                                               â”‚ â”‚
â”‚ â”‚ â€¢ Term: Hepatic enzyme increased                        â”‚ â”‚
â”‚ â”‚ â€¢ Documented Severity: Grade 1-2 (Mild to Moderate)    â”‚ â”‚
â”‚ â”‚ â€¢ Documented Frequency: Common (5-10%)                 â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚ âš ï¸ Severity exceeds IB documentation                   â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ Is event at specificity/severity documented in IB?         â”‚
â”‚ â—‹ Yes, as documented  â— No, more severe than documented   â”‚
â”‚                                                             â”‚
â”‚ DETERMINATION: â— UNEXPECTED                                 â”‚
â”‚                â—‹ Expected                                   â”‚
â”‚                                                             â”‚
â”‚ Justification:                                              â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ Grade 3 severity not documented in IB which only lists â”‚ â”‚
â”‚ â”‚ Grade 1-2. Therefore unexpected per 21 CFR 312.32(a).  â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.5 Report Classification Interface

#### REQ-UI-CLASS-001: SUSAR Determination
```
Report classification summary:

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Report Classification                                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ CRITERIA CHECKLIST                                          â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚ [âœ“] Serious (hospitalization, life-threatening, etc.)      â”‚
â”‚ [âœ“] Suspected Adverse Reaction (evidence of causality)     â”‚
â”‚ [âœ“] Unexpected (not in IB at severity observed)            â”‚
â”‚                                                             â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ ğŸš¨ This is a SUSAR (Suspected Unexpected Serious        â”‚ â”‚
â”‚ â”‚    Adverse Reaction)                                    â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚    Expedited reporting to FDA is REQUIRED              â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ TIMELINE DETERMINATION                                      â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚                                                             â”‚
â”‚ Is event fatal or life-threatening?                        â”‚
â”‚ â— Yes - Life-threatening                                   â”‚
â”‚ â—‹ No                                                       â”‚
â”‚                                                             â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ â° 7-DAY REPORT REQUIRED                                â”‚ â”‚
â”‚ â”‚                                                         â”‚ â”‚
â”‚ â”‚ Date Informed: January 20, 2026                        â”‚ â”‚
â”‚ â”‚ Due Date: January 27, 2026                             â”‚ â”‚
â”‚ â”‚ Days Remaining: 5                                       â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ Report Type: â— 7-Day IND Safety Report                     â”‚
â”‚              â—‹ 15-Day IND Safety Report                    â”‚
â”‚              â—‹ Follow-up Report                            â”‚
â”‚              â—‹ Annual Report Only                          â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.6 Unblinding Interface

#### REQ-UI-UNBLIND-001: Unblinding Request
```
Unblinding request dialog:

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Request Unblinding                                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ Case: IND-2026-001234                                       â”‚
â”‚ Subject: SUBJ-2026-0042                                     â”‚
â”‚ Study: ABC-001-2026                                         â”‚
â”‚                                                             â”‚
â”‚ Current Status: BLINDED                                     â”‚
â”‚                                                             â”‚
â”‚ âš ï¸ Unblinding is irreversible and may impact study         â”‚
â”‚    integrity. Proceed only when medically necessary.       â”‚
â”‚                                                             â”‚
â”‚ Reason for Unblinding:                                      â”‚
â”‚ â— Medical emergency / subject safety                       â”‚
â”‚ â—‹ Serious unexpected event requiring treatment knowledge   â”‚
â”‚ â—‹ Regulatory request                                        â”‚
â”‚ â—‹ Sponsor safety assessment                                 â”‚
â”‚ â—‹ Study completion / database lock                         â”‚
â”‚ â—‹ Other: [________________________]                        â”‚
â”‚                                                             â”‚
â”‚ Justification:                                              â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ Subject experiencing Grade 4 hepatotoxicity requiring  â”‚ â”‚
â”‚ â”‚ immediate medical intervention. Treatment knowledge    â”‚ â”‚
â”‚ â”‚ needed for appropriate management.                      â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                             â”‚
â”‚ Requestor: Dr. Jane Smith (Investigator)                   â”‚
â”‚ Date/Time: 2026-01-22 14:35 UTC                            â”‚
â”‚                                                             â”‚
â”‚              [Cancel]  [Submit Unblinding Request]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 5. Data Model Updates

### 5.1 Study and Site Tables

```sql
-- Clinical studies
CREATE TABLE studies (
    id SERIAL PRIMARY KEY,
    study_id VARCHAR(50) UNIQUE NOT NULL, -- Internal ID
    protocol_number VARCHAR(100) NOT NULL,
    study_title VARCHAR(500) NOT NULL,
    sponsor_name VARCHAR(255),
    phase VARCHAR(20), -- Phase 1, 1/2, 2, 2/3, 3, 3b, 4
    study_design VARCHAR(100),
    therapeutic_area VARCHAR(100),
    indication TEXT,
    target_enrollment INTEGER,
    status VARCHAR(20) DEFAULT 'planned',
        -- planned, enrolling, active, completed, terminated
    fpfv_date DATE, -- First patient first visit
    lplv_date DATE, -- Last patient last visit
    is_blinded BOOLEAN DEFAULT FALSE,
    created_by INTEGER REFERENCES users(id),
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP,
    updated_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);

-- Study IND numbers (many-to-many)
CREATE TABLE study_inds (
    id SERIAL PRIMARY KEY,
    study_id INTEGER REFERENCES studies(id),
    ind_number VARCHAR(10) NOT NULL, -- 6-digit IND
    center VARCHAR(10) NOT NULL, -- CDER, CBER
    is_primary BOOLEAN DEFAULT FALSE,
    UNIQUE(study_id, ind_number)
);

-- Study sites
CREATE TABLE study_sites (
    id SERIAL PRIMARY KEY,
    study_id INTEGER REFERENCES studies(id),
    site_number VARCHAR(20) NOT NULL,
    site_name VARCHAR(255) NOT NULL,
    institution_name VARCHAR(255),
    address_line1 VARCHAR(255),
    address_line2 VARCHAR(255),
    city VARCHAR(100),
    state VARCHAR(50),
    postal_code VARCHAR(20),
    country VARCHAR(100) NOT NULL,
    phone VARCHAR(50),
    fax VARCHAR(50),
    email VARCHAR(255),
    status VARCHAR(20) DEFAULT 'active',
        -- pending, active, suspended, closed
    first_enrollment_date DATE,
    irb_name VARCHAR(255),
    irb_approval_date DATE,
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP,
    UNIQUE(study_id, site_number)
);

-- Site investigators
CREATE TABLE site_investigators (
    id SERIAL PRIMARY KEY,
    site_id INTEGER REFERENCES study_sites(id),
    investigator_name VARCHAR(255) NOT NULL,
    role VARCHAR(50) NOT NULL, -- PI, Sub-I, Study Coordinator
    email VARCHAR(255),
    phone VARCHAR(50),
    is_primary BOOLEAN DEFAULT FALSE,
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);

-- Investigational products
CREATE TABLE study_products (
    id SERIAL PRIMARY KEY,
    study_id INTEGER REFERENCES studies(id),
    product_name VARCHAR(255) NOT NULL,
    active_ingredient VARCHAR(255),
    dosage_form VARCHAR(100),
    strength VARCHAR(100),
    route VARCHAR(50),
    is_investigational BOOLEAN DEFAULT TRUE,
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);

-- Investigator Brochure versions
CREATE TABLE investigator_brochures (
    id SERIAL PRIMARY KEY,
    study_id INTEGER REFERENCES studies(id),
    version_number VARCHAR(20) NOT NULL,
    effective_date DATE NOT NULL,
    document_path TEXT,
    change_summary TEXT,
    is_current BOOLEAN DEFAULT FALSE,
    created_by INTEGER REFERENCES users(id),
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP,
    UNIQUE(study_id, version_number)
);

-- IB known adverse reactions (for expectedness lookup)
CREATE TABLE ib_known_reactions (
    id SERIAL PRIMARY KEY,
    ib_id INTEGER REFERENCES investigator_brochures(id),
    meddra_pt_code INTEGER NOT NULL,
    meddra_pt_name VARCHAR(255) NOT NULL,
    documented_severity VARCHAR(50), -- Mild, Moderate, Severe, Grade 1-4
    documented_frequency VARCHAR(50), -- Common, Uncommon, Rare, etc.
    ib_section VARCHAR(50),
    ib_page VARCHAR(20),
    notes TEXT,
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);
```

### 5.2 IND Case Extensions

```sql
-- IND-specific case fields
ALTER TABLE cases ADD COLUMN case_type VARCHAR(20) DEFAULT 'postmarket';
    -- postmarket, ind, babe
ALTER TABLE cases ADD COLUMN study_id INTEGER REFERENCES studies(id);
ALTER TABLE cases ADD COLUMN site_id INTEGER REFERENCES study_sites(id);
ALTER TABLE cases ADD COLUMN subject_number VARCHAR(50);
ALTER TABLE cases ADD COLUMN is_blinded BOOLEAN DEFAULT FALSE;
ALTER TABLE cases ADD COLUMN treatment_arm VARCHAR(100);
ALTER TABLE cases ADD COLUMN study_day_onset INTEGER;
ALTER TABLE cases ADD COLUMN first_dose_date DATE;
ALTER TABLE cases ADD COLUMN last_dose_date DATE;
ALTER TABLE cases ADD COLUMN date_informed DATE; -- Date sponsor informed

-- Expectedness assessment
ALTER TABLE cases ADD COLUMN is_expected BOOLEAN;
ALTER TABLE cases ADD COLUMN expectedness_ib_version VARCHAR(20);
ALTER TABLE cases ADD COLUMN expectedness_ib_section VARCHAR(50);
ALTER TABLE cases ADD COLUMN expectedness_justification TEXT;

-- Report type for IND
ALTER TABLE cases ADD COLUMN ind_report_type VARCHAR(20);
    -- 7_day, 15_day, followup_7day, followup_15day, annual_only

-- Causality assessments
CREATE TABLE case_causality (
    id SERIAL PRIMARY KEY,
    case_id TEXT REFERENCES cases(case_id),
    assessor_type VARCHAR(20) NOT NULL, -- investigator, sponsor, independent
    assessor_name VARCHAR(255),
    assessment_date DATE NOT NULL,
    relationship VARCHAR(50) NOT NULL,
        -- related, probably_related, possibly_related, 
        -- unlikely_related, not_related, not_assessable
    justification TEXT,
    created_by INTEGER REFERENCES users(id),
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);

-- Unblinding records
CREATE TABLE case_unblinding (
    id SERIAL PRIMARY KEY,
    case_id TEXT REFERENCES cases(case_id),
    request_date TIMESTAMP NOT NULL,
    request_reason VARCHAR(50) NOT NULL,
        -- medical_emergency, serious_unexpected, regulatory,
        -- sponsor_assessment, study_completion, other
    request_justification TEXT,
    requested_by INTEGER REFERENCES users(id),
    approval_required BOOLEAN DEFAULT TRUE,
    approved_by INTEGER REFERENCES users(id),
    approved_at TIMESTAMP,
    unblinding_date TIMESTAMP,
    treatment_arm_revealed VARCHAR(100),
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);
```

### 5.3 BA/BE Study Tables

```sql
-- BA/BE studies
CREATE TABLE babe_studies (
    id SERIAL PRIMARY KEY,
    protocol_number VARCHAR(100) NOT NULL,
    study_design VARCHAR(50), -- crossover, parallel, replicate
    test_product_name VARCHAR(255) NOT NULL,
    test_product_manufacturer VARCHAR(255),
    reference_product_name VARCHAR(255) NOT NULL,
    reference_product_manufacturer VARCHAR(255),
    active_ingredient VARCHAR(255),
    dosage_form VARCHAR(100),
    strength VARCHAR(100),
    population VARCHAR(50), -- healthy_volunteers, patients
    sponsor_name VARCHAR(255),
    pre_anda_number VARCHAR(20),
    status VARCHAR(20) DEFAULT 'active',
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);
```

### 5.4 Protocol Deviations

```sql
-- Protocol deviations
CREATE TABLE protocol_deviations (
    id SERIAL PRIMARY KEY,
    deviation_id VARCHAR(50) UNIQUE NOT NULL,
    study_id INTEGER REFERENCES studies(id),
    site_id INTEGER REFERENCES study_sites(id),
    subject_number VARCHAR(50),
    deviation_date DATE NOT NULL,
    category VARCHAR(50) NOT NULL,
        -- inclusion_exclusion, informed_consent, prohibited_med,
        -- dose_modification, visit_schedule, specimen, other
    description TEXT NOT NULL,
    impact_on_safety TEXT,
    impact_on_data TEXT,
    corrective_action TEXT,
    reported_to_irb BOOLEAN DEFAULT FALSE,
    irb_report_date DATE,
    reported_to_sponsor BOOLEAN DEFAULT FALSE,
    sponsor_report_date DATE,
    created_by INTEGER REFERENCES users(id),
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);

-- Deviation-case link
CREATE TABLE deviation_cases (
    deviation_id INTEGER REFERENCES protocol_deviations(id),
    case_id TEXT REFERENCES cases(case_id),
    PRIMARY KEY (deviation_id, case_id)
);
```

### 5.5 Investigator Notifications

```sql
-- Investigator safety notifications
CREATE TABLE investigator_notifications (
    id SERIAL PRIMARY KEY,
    notification_type VARCHAR(50) NOT NULL,
        -- susar_alert, ib_update, safety_finding
    study_id INTEGER REFERENCES studies(id),
    case_id TEXT REFERENCES cases(case_id),
    notification_date DATE NOT NULL,
    subject_line VARCHAR(255),
    content TEXT,
    attachment_path TEXT,
    created_by INTEGER REFERENCES users(id),
    created_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
);

-- Notification distribution
CREATE TABLE notification_distribution (
    id SERIAL PRIMARY KEY,
    notification_id INTEGER REFERENCES investigator_notifications(id),
    site_id INTEGER REFERENCES study_sites(id),
    recipient_name VARCHAR(255),
    recipient_email VARCHAR(255),
    sent_date TIMESTAMP,
    acknowledged_date TIMESTAMP,
    acknowledged_by VARCHAR(255)
);
```

---

## 6. API Endpoints

### 6.1 Study Management API

```yaml
# Studies
GET /api/v1/studies
  Description: List all studies
  Query: status, phase, therapeutic_area
  Response: Study list

POST /api/v1/studies
  Description: Create study
  Body: Study fields
  Response: Created study

GET /api/v1/studies/{id}
  Description: Get study details with sites, products, IB
  Response: Complete study object

PUT /api/v1/studies/{id}
  Description: Update study
  Body: Study updates
  Response: Updated study

# Study Sites
GET /api/v1/studies/{id}/sites
  Description: List sites for study
  Response: Site list with investigators

POST /api/v1/studies/{id}/sites
  Description: Add site to study
  Body: Site fields
  Response: Created site

# Investigator Brochure
GET /api/v1/studies/{id}/ib
  Description: List IB versions
  Response: IB version list

POST /api/v1/studies/{id}/ib
  Description: Add IB version
  Body: IB fields and file
  Response: Created IB version

GET /api/v1/studies/{id}/ib/{version}/reactions
  Description: Get known reactions for IB version
  Response: Reaction list for expectedness lookup
```

### 6.2 IND Case API

```yaml
POST /api/v1/cases/ind
  Description: Create IND safety report
  Body: IND case fields
  Response: Created case

GET /api/v1/cases/{id}/causality
  Description: Get causality assessments
  Response: Investigator and sponsor assessments

POST /api/v1/cases/{id}/causality
  Description: Add/update causality assessment
  Body: Assessment fields
  Response: Updated assessments

POST /api/v1/cases/{id}/expectedness
  Description: Assess expectedness
  Body: Expectedness determination
  Response: Expectedness result

POST /api/v1/cases/{id}/unblind
  Description: Request unblinding
  Body: Reason, justification
  Response: Unblinding request

PUT /api/v1/cases/{id}/unblind/{request_id}/approve
  Description: Approve unblinding request
  Body: Approval details
  Response: Unblinding completed
```

### 6.3 Form 3500A API

```yaml
POST /api/v1/cases/{id}/form-3500a
  Description: Generate Form FDA 3500A
  Response: PDF file path

GET /api/v1/cases/{id}/form-3500a/preview
  Description: Preview form before generation
  Response: Preview data with validation

GET /api/v1/cases/{id}/form-3500a/download
  Description: Download generated PDF
  Response: PDF file
```

### 6.4 Annual Report API

```yaml
POST /api/v1/studies/{id}/annual-report/generate
  Description: Generate annual report data
  Body: 
    period_start: date
    period_end: date
  Response: Report data and statistics

GET /api/v1/studies/{id}/annual-report/cases
  Description: Get cases for annual report
  Query: period_start, period_end
  Response: Case list with categorization

GET /api/v1/studies/{id}/annual-report/export
  Description: Export annual report tables
  Query: period_start, period_end
  Response: Excel file
```

### 6.5 Protocol Deviation API

```yaml
GET /api/v1/studies/{id}/deviations
  Description: List deviations for study
  Query: category, site, subject
  Response: Deviation list

POST /api/v1/studies/{id}/deviations
  Description: Create deviation
  Body: Deviation fields
  Response: Created deviation

POST /api/v1/cases/{id}/deviations/link
  Description: Link deviation to case
  Body: deviation_id
  Response: Linked deviation

GET /api/v1/cases/{id}/deviations
  Description: Get deviations linked to case
  Response: Linked deviation list
```

---

## 7. Testing Requirements

### 7.1 IND Case Testing

| Test Case | Expected Result |
|-----------|-----------------|
| Create IND case | All IND fields captured |
| Select study | IND auto-populated from study |
| Select site | Investigator info populated |
| Blinded case creation | Treatment arm hidden |
| Causality entry | Both assessments required |
| Expectedness lookup | IB reaction matched |
| SUSAR determination | 7-day or 15-day calculated |
| Due date calculation | Correct based on timeline |

### 7.2 Blinding Testing

| Test Case | Expected Result |
|-----------|-----------------|
| Blinded case display | Treatment arm shows "Blinded" |
| Unblinding request | Request recorded with reason |
| Unblinding approval | Treatment arm revealed |
| Post-unblind update | Causality re-assessment prompted |

### 7.3 XML Testing

| Test Case | Expected Result |
|-----------|-----------------|
| IND XML routing | ZZFDA_PREMKT batch receiver |
| IND number in XML | A.1.6 populated correctly |
| Report type 7-day | FDA.C.1.7.1 = 6 |
| Report type 15-day | FDA.C.1.7.1 = 5 |
| BA/BE routing | CDER_IND_EXEMPT_BA_BE receiver |

### 7.4 Form 3500A Testing

| Test Case | Expected Result |
|-----------|-----------------|
| Generate PDF | All fields populated |
| Required fields | Validated before generation |
| Date formatting | dd-mmm-yyyy format |
| Long narrative | Continuation page used |
| Preview function | Editable before final |

---

## 8. Acceptance Criteria Summary

### 8.1 Must Have
- [ ] IND case type with all required fields
- [ ] Study/protocol configuration
- [ ] Site and investigator management
- [ ] Causality assessment (investigator + sponsor)
- [ ] Expectedness assessment with IB reference
- [ ] 7-day and 15-day timeline calculation
- [ ] Blinded case handling
- [ ] Unblinding workflow
- [ ] Form FDA 3500A generation
- [ ] E2B(R3) XML with IND routing
- [ ] BA/BE study support

### 8.2 Should Have
- [ ] IB known reactions database for lookup
- [ ] Protocol deviation tracking
- [ ] Annual report data aggregation
- [ ] Investigator notification generation
- [ ] SUSAR auto-classification

### 8.3 Nice to Have
- [ ] IB document comparison
- [ ] Investigator notification tracking
- [ ] IRB submission tracking
- [ ] Deviation-case linking
- [ ] Annual report narrative generation

---

## 9. Configuration Options

```yaml
# config/phase6.yaml

ind:
  require_both_causality_assessments: true
  require_expectedness_justification: true
  require_unblinding_approval: true
  default_center: CDER  # or CBER
  
timeline:
  fatal_life_threatening_days: 7
  other_susar_days: 15
  followup_days: 15
  
blinding:
  allow_self_unblinding: false
  unblinding_approvers: ["medical_monitor", "safety_lead"]
  
form_3500a:
  company_name: "Acme Pharmaceuticals"
  company_address: "123 Main St, Boston, MA 02101"
  company_phone: "(555) 123-4567"
  
annual_report:
  default_period_months: 12
  include_expected_sae: true
  include_non_serious: false
```

---

## 10. References

- [21 CFR 312.32](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32) - IND Safety Reporting
- [21 CFR 320.31](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-320/subpart-B/section-320.31) - BA/BE Study Requirements
- [FDA Guidance: IND Safety Reports](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-ind-safety-reports) - Electronic Submission Format
- [FDA E2B(R3) IND Technical Conformance Guide](https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submissions-e2br3-standards)
- [Form FDA 3500A](https://www.fda.gov/safety/medwatch-forms-fda-safety-reporting) - Mandatory Reporting Form
- [ICH E2A](https://database.ich.org/sites/default/files/E2A_Guideline.pdf) - Clinical Safety Data Management
- [ICH E6(R2)](https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf) - Good Clinical Practice
- Phase 5 Requirements: `05_Phase5_DataManagement_Terminology.md`

---

## Next Phase

After completing Phase 6, proceed to **Phase 7: Cosmetics & Multi-Regulatory** which adds:
- MoCRA compliance for cosmetics adverse event reporting
- E2B(R2) format for cosmetics (required by FDA)
- Support for EudraVigilance (EU) submissions
- Multi-regulatory submission management
